U.S. Stocks Plummet Amid Downgrades: Vivid Seats and Y-mAbs Therapeutics Cut to Hold

Two companies, Vivid Seats and Y-mAbs Therapeutics, have been downgraded by analysts. Vivid Seats was cut to "Hold" from "Buy" by Canaccord Genuity, while Y-mAbs Therapeutics was cut to "Neutral" from "Buy" by HC Wainwright & Co. The downgrades are based on market performance and other factors.

Title: Analyst Downgrades for Vivid Seats and Y-mAbs Therapeutics

Two companies, Vivid Seats and Y-mAbs Therapeutics, have recently been downgraded by analysts. Vivid Seats was cut to "Hold" from "Buy" by Canaccord Genuity, while Y-mAbs Therapeutics was downgraded to "Neutral" from "Buy" by HC Wainwright & Co. These downgrades are based on recent market performance and other factors.

# Vivid Seats

Canaccord Genuity downgraded Vivid Seats Inc. (NASDAQ:SEAT) from "Buy" to "Hold" following disappointing second-quarter results. The stock has fallen over 76% in the past six months, trading near its 52-week low of $19.58. The ticket marketplace reported a decline of more than 30% year-over-year in gross order value (GOV) during Q2, worsening from a 20% decline in Q1. Despite maintaining a robust gross profit margin of 74%, the performance deterioration primarily reflected intensifying competitive pressures [1].

Vivid Seats management expects competitive intensity to persist throughout the remainder of the year, forecasting the industry to be flat to slightly down for fiscal year 2025. In response, the company announced it is shutting down its Vivid Picks offering and implementing a $25 million cost reduction initiative to preserve unit economics [2]. The company's Q2 2025 earnings revealed mixed performance, slightly exceeding expectations on earnings per share (EPS) but falling short of revenue projections [2].

# Y-mAbs Therapeutics

HC Wainwright & Co. downgraded Y-mAbs Therapeutics (NASDAQ:YMAB) from "Buy" to "Neutral" following the announcement of its acquisition by SERB Pharmaceuticals. The acquisition, valued at approximately $412 million, represents a 105% premium to the company’s closing share price on August 4, 2025. Despite the acquisition, the stock has declined over 15% in the past week [3].

The acquisition is expected to close by the fourth quarter of 2025 and will transfer Y-mAbs’ commercial asset Danyelza and its development pipeline to SERB Pharmaceuticals. Y-mAbs’ pipeline includes GD2 therapy targeting solid tumors and CD38 therapy in circulating tumors currently in Phase 1 development, which will complement SERB’s existing rare oncology portfolio [3].

In other recent news, Y-mAbs Therapeutics exceeded earnings expectations with an earnings per share of -$0.12, compared to the forecasted -$0.1911. The company’s revenue for the first quarter of 2025 was reported at $20.9 million, closely aligning with the projected $20.84 million [3].

References

[1] https://www.investing.com/news/analyst-ratings/canaccord-genuity-downgrades-vivid-seats-stock-amid-competitive-pressures-93CH-4172109
[2] https://za.investing.com/news/analyst-ratings/canaccord-genuity-downgrades-vivid-seats-stock-amid-competitive-pressures-93CH-3821710
[3] https://www.investing.com/news/analyst-ratings/ymabs-therapeutics-stock-downgraded-to-hold-by-truist-after-serb-acquisition-93CH-4171219